Sector: Health Care
Director information for INSULET CORP (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Ashley A. McEvoy | President and Chief Executive Officer, Insulet Corporation; Director, President and Chief Executive Officer; Principal Executive Officer | 55 | ["Former Executive Vice President, Worldwide Chairman of MedTech at Johnson & Johnson","Led significant and diverse businesses with a global footprint","Driving strategic investments in innovation platforms and commercial executions","Company Group Chairman, Consumer Medical Devices from 2014 to 2018","Company Group Chairman, Vision Care from 2012 to 2014","Worldwide President, Ethicon Products from 2009 to 2011","President, McNeil Consumer Healthcare from 2006 to 2009","Vice President, Marketing and General Manager, McNeil Labs from 2003 to 2006","Joined J&J in 1996 as an Assistant Brand Manager","Over 25 years at Johnson & Johnson","Executive Vice President, Worldwide Chairman of MedTech","Leadership, strategy, and risk management experience"] | [] | 2026 |
| Elizabeth H. Weatherman | Board Chair; Special Limited Partner, Warburg Pincus | 66 | ["Special Limited Partner of Warburg Pincus since January 2016","Joined Warburg Pincus in 1988","Led firm’s Healthcare Group from 2008 to 2015","Managing Director and member of the firm’s Executive Management Group","Director of Royalty Pharma","Director of Stanford Health Care","Trustee of Stanford University","Trustee and chair of the Investment Committee of Mount Holyoke College","BA in English from Mount Holyoke College","MBA from the Stanford Graduate School of Business","Chair"] | ["Talent and Compensation (Chair)","Nominating","Governance and Risk","Talent and Compensation","Nominating, Governance and Risk Committee"] | 2026 |
| Flavia H. Pease | Executive Vice President and Chief Financial Officer | 53 | ["international perspective","financial acumen","business development experience","Executive Vice President and Chief Financial Officer at Insulet","Corporate Executive Vice President and Chief Financial Officer at Charles River Laboratories","Vice President and Group Chief Financial Officer of Johnson & Johnson’s global Medical Devices businesses","More than 20 years in financial leadership roles at J&J","Vice President, Finance for Janssen North America","Vice President of the Enterprise Program Management Office at J&J","Led integration of Mentor and Acclarent acquisitions","Held various finance leadership positions within Mergers and Acquisitions Analysis and J&J Medical Brazil","Bachelor of Science in Economics from Pontifícia Universidade Católica","Master of Business Administration from Santa Clara University Leavy School of Business"] | ["Audit Committee"] | 2026 |
| Jessica Hopfield | Chair | [] | ["Nominating, Governance and Risk Committee"] | 2026 | |
| Jessica Hopfield, Ph.D. | Strategic advisor to healthcare and technology firms; Director | 61 | ["Chair","NACD Directorship certified","Healthcare executive","Diabetes expert","Over two decades of experience in the medical and healthcare fields","Strategic advisor and investor in healthcare and technology firms","Principal at J Hopfield Consulting","Former Chair of the Board of Trustees of the Joslin Diabetes Center","Partner at McKinsey & Company","Management positions at Merck Sharp & Dohme Corp.","PhD in Neuroscience/Biochemistry from The Rockefeller University","MBA from Harvard Business School as a Baker Scholar","Bachelor of Science from Yale College"] | ["Nominating, Governance and Risk Committee","Nominating","Governance and Risk (Chair)","Science and Technology"] | 2026 |
| Luciana Borio | Venture Partner, ARCH VenturePartners; Director | 55 | [] | ["Talent and Compensation Committee","Science and Technology Committee"] | 2026 |
| Luciana Borio, M.D. | Venture Partner, ARCH Venture Partners; Director | 55 | ["NACD Directorship certified","Venture partner at ARCH Venture Partners","Adjunct faculty member at Johns Hopkins Hospital","Senior fellow for Global Health at the Council on Foreign Relations","Specialist in biodefense, emerging infectious diseases, and medical product development","Member of the President’s Transition COVID-19 Advisory Board in 2020","Senior Vice President at In-Q-Tel","Director for Medical and Biodefense Preparedness Policy at the National Security Council","Acting Chief Scientist and Assistant Commissioner for Counterterrorism Policy at the U.S. FDA","Developed responses to public health emergencies such as H1N1, Ebola, and Zika","Served on World Health Organization’s Emergency Preparedness and Response Scientific Advisory Group","Doctor of Medicine from George Washington University School of Medicine","Bachelor of Science in Zoology from George Washington University"] | ["Audit Committee","Nominating, Governance and Risk Committee","Talent and Compensation","Science and Technology"] | 2026 |
| Michael R. Minogue | President and Chief Executive Officer Minogue Consulting, LLC and Heartwork Capital, LLC; President and CEO; Member; Director | 59 | ["President and CEO of Minogue Consulting, LLC and Heartwork Capital, LLC","Former Chairman of the Board, President and Chief Executive Officer of Abiomed, Inc.","11 years at General Electric Healthcare in various leadership roles","Director of the Advanced Medical Technology Association (AdvaMed)","Chairman of the Governor’s Advisory Council on Veterans’ Services for Massachusetts","Served as an officer in the U.S. Army receiving multiple distinctions","Bachelor of Science in Engineering Management from the United States Military Academy at West Point","MBA from the University of Chicago Graduate School of Business","financially literate","audit committee financial expert"] | ["Audit Committee","Audit"] | 2026 |
| Robert L. Huffines | Founder of The Forest Group, Retired Global Chair of Investment Banking at JP Morgan Chase; Director; Member | 60 | ["Co-founder of The Forest Group","Global chair, investment banking of J.P. Morgan Chase & Co. (2017-2024)","Vice chair of investment banking at J.P. Morgan (2011-2017)","Co-head of global healthcare investment banking group at J.P. Morgan (2002-2010)","Various positions in healthcare mergers and acquisitions and healthcare industry groups at J.P. Morgan (1992-2002)","Worked at Alex Brown & Sons specializing in equity financing and advisory assignments for emerging growth companies","Member of the board of directors of Becton, Dickinson and Company, Eikon Therapeutics, Hastings Center for Biomedical Ethics, Nextech Invest Ltd.","Former board member of Walgreens Boots Alliance","M.B.A. from University of Virginia Darden School of Business","B.A. from University of North Carolina at Chapel Hill in English and Economics","More than 30 years of experience advising healthcare companies on strategy, mergers and acquisitions, divestitures and financing","Former Global Chair of Investment Banking at JP Morgan Chase & Co.","Over 30 years of experience advising healthcare companies","Strategic insight and deep industry knowledge","financially literate","audit committee financial expert"] | ["Audit Committee","Nominating, Governance and Risk Committee","Audit","Nominating","Governance and Risk","Nominating,Governance and Risk"] | 2026 |
| Timothy C. Stonesifer | Chief Financial Officer, Alcon Inc.; Director; Chair | 58 | ["Chair","Chief Financial Officer at Alcon Inc.","Executive Vice President and Chief Financial Officer at Hewlett Packard Enterprise Corporation","Senior Vice President and Chief Financial Officer, Enterprise Group at HP","Chief Financial Officer of General Motors’ International Operations","Chief Financial Officer of Alegco Scotsman","Chief Financial Officer of Sabic Innovative Plastics","Various positions at General Electric","Bachelor of Arts in Economics from the University of Michigan","International perspective","Significant financial expertise","financial acumen","operational experience","deep experience in capital markets transactions","senior executive leadership","international experience","financially literate","audit committee financial expert"] | ["Talent and Compensation Committee","Audit Committee (CHAIR)","Audit (Chair)","Audit Committee"] | 2026 |
| Timothy J. Scannell | Retired President and Chief Operating Officer, Stryker Corporation; Chairman of the Board | 61 | ["Board Chair from January 2019 to December 2025","Executive Advisor at Stryker Corporation","President and Chief Operating Officer at Stryker","Group President overseeing Stryker’s MedSurg and Neurotechnology divisions","Various roles at Stryker from 1990 to 2009","Bachelor of Business Administration and a Master of Business Administration from the University of Notre Dame","Extensive strategic, organizational, and operational skills and experience"] | ["Nominating, Governance and Risk Committee","Nominating","Governance and Risk","Talent and Compensation"] | 2026 |
| Wayne A.I. Frederick | [] | ["Nominating,Governance and Risk","Talent and Compensation"] | 2026 | ||
| Wayne A. I. Frederick, M.D. | Interim President, Howard University | 54 | ["President Emeritus of Howard University","Interim Chief Executive Officer of the American Cancer Society","distinguished Charles R. Drew Professor of Surgery","practicing cancer surgeon","distinguished researcher and scholar","expert in health care disparities and medical education","numerous peer-reviewed articles, book chapters, abstracts, and editorials","current board member of Agostini Limited, Humana, Inc., Tempus AI, Inc. and Workday, Inc.","senior independent director of Mutual of America","Senior Advisor for Blackstone Inc.","Bachelor of Science, Doctor of Medicine, and Master of Business Administration from Howard University"] | ["Audit Committee","Nominating, Governance and Risk Committee","Talent and Compensation","Science and Technology (Chair)"] | 2026 |
